Lyon-based investment platform Mérieux Equity Partners has closed its new investment fund dedicated to the healthcare and nutrition sectors, oversubscribed at €377m (US$418.5m).
Mérieux Participations 3 was launched with the support of Institut Mérieux as a sponsor and an initial hard cap of €350m. In December 2019, the new vehicle closed at €377m, with commitments from leading European family holdings and institutions.
As part of its development, Mérieux Equity Partners expanded its investment team in 2019 with the appointment of Marie-Justine Lecomte and Romain Chevrillon as Associates within the growth capital and buy-out team and now employs 16 staff members in Lyon, Paris and Boston.
To date, Mérieux Participations 3 has completed seven transactions in France and Europe, including four majority deals.
In 2019, Mérieux Equity Partners invested in Addmedica – a French specialty pharmaceutical company engaged in rare diseases, Doc Generici – Italy’s largest independent generic pharmaceutical company – and more recently Mabtech, a Swedish life science company specialized in immune monitoring.